Plasmodium falciparum Antigen Expression in Parasite: A Way Forward for Live Attenuated Vaccine Development

Author(s):  
Akriti Srivastava ◽  
Swati Garg ◽  
Sweta Karan ◽  
Shikha Kaushik ◽  
Anand Ranganathan ◽  
...  
2020 ◽  
Vol 12 (529) ◽  
pp. eaba9014
Author(s):  
Michelle Boyle

Vaccination with a Bordetella pertussis live attenuated vaccine induces a beneficial TH1 cell bias and broadly targeting functional antibodies in humans.


Vaccines ◽  
2020 ◽  
Vol 8 (1) ◽  
pp. 63 ◽  
Author(s):  
Sheng-Qun Deng ◽  
Xian Yang ◽  
Yong Wei ◽  
Jia-Ting Chen ◽  
Xiao-Jun Wang ◽  
...  

Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.


PLoS ONE ◽  
2008 ◽  
Vol 3 (7) ◽  
pp. e2824 ◽  
Author(s):  
Jeffrey B. Locke ◽  
Ramy K. Aziz ◽  
Mike R. Vicknair ◽  
Victor Nizet ◽  
John T. Buchanan

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Mohammad Javad Abbaszadeh Afshar ◽  
Samira Elikaee ◽  
Reza Saberi ◽  
Sina Mohtasebi ◽  
Mehdi Mohebali

Abstract Background Leishmania parasites express various essential proteins in different growth phases (logarithmic/stationary) and forms (promastigote/amastigote). Targeting the genes encoding such proteins paves the way for controlling these parasites. Centrin is an essential gene, which its protein product seems to be vital for the proliferation of Leishmania parasites. Herein, this study was contrived to analyze the expression level of the centrin gene in different growth phases and forms of Leishmania infantum (L. infantum) parasites isolated from various endemic areas of canine leishmaniasis (CanL) in Iran. Results All three collected isolates were identified as L. infantum using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Real-time reverse transcription (RT)-PCR revealed a statistically significant up-regulation (3.13-fold) in the logarithmic phase promastigotes compared to stationary ones (p < 0.01), whereas centrin was expressed equally in intracellular amastigotes at different time points during cell culture. Also, our finding revealed a slight up-regulation of the centrin gene (1.22-fold) in the intracellular amastigotes compared to logarithmic phase promastigotes, which was found statistically non-significant (p > 0.05). Conclusions Centrin gene in Iranian isolates of L. infantum is more expressed in exponential than stationary phases and seems to be considered as a promising target in the development of a genetically modified live attenuated vaccine for CanL control.


2000 ◽  
Vol 68 (3) ◽  
pp. 1171-1175 ◽  
Author(s):  
Manohar John ◽  
Thomas I. Crean ◽  
Stephen B. Calderwood ◽  
Edward T. Ryan

ABSTRACT The optimal promoter for in vivo expression of heterologous antigens by live, attenuated vaccine vector strains of Vibrio cholerae is unclear; in vitro analyses of promoter activity may not accurately predict expression of antigens in vivo. We therefore introduced plasmids expressing the B subunit of cholera toxin (CtxB) under the control of a number of promoters into V. choleraevaccine strain Peru2. We evaluated the tac promoter, which is constitutively expressed in V. cholerae, as well as the in vivo-induced V. cholerae heat shock htpGpromoter and the in vivo-induced V. cholerae iron-regulatedirgA promoter. The functionality of all promoters was confirmed in vitro. In vitro antigenic expression was highest in vaccine strains expressing CtxB under the control of thetac promoter (2 to 5 μg/ml/unit of optical density at 600 nm [OD600]) and, under low-iron conditions, in strains containing the irgA promoter (5 μg/ml/OD600). We orally inoculated mice with the various vaccine strains and used anti-CtxB immune responses as a marker for in vivo expression of CtxB. The vaccine strain expressing CtxB under the control of thetac promoter elicited the most prominent specific anti-CtxB responses in vivo (serum immunoglobulin G [IgG], P≤ 0.05; serum IgA, P ≤ 0.05; stool IgA,P ≤ 0.05; bile IgA, P ≤ 0.05), despite the finding that the tac and irgApromoters expressed equivalent amounts of CtxB in vitro. Vibriocidal antibody titers were equivalent in all groups of animals. Our results indicate that in vitro assessment of antigen expression by vaccine and vector strains of V. cholerae may correlate poorly with immune responses in vivo and that of the promoters examined, thetac promoter may be best suited for expression from plasmids of at least certain heterologous antigens in such strains.


2000 ◽  
Vol 68 (1) ◽  
pp. 221-226 ◽  
Author(s):  
Edward T. Ryan ◽  
Thomas I. Crean ◽  
Sims K. Kochi ◽  
Manohar John ◽  
Angel A. Luciano ◽  
...  

ABSTRACT We have previously shown that more prominent immune responses are induced to antigens expressed from multicopy plasmids in live attenuated vaccine vector strains of Vibrio cholerae than to antigens expressed from single-copy genes on the V. cholerae chromosome. Here, we report the construction of a ΔglnA derivative of V. cholerae vaccine strain Peru2. This mutant strain, Peru2ΔglnA, is unable to grow on medium that does not contain glutamine; this growth deficiency is complemented by pKEK71-NotI, a plasmid containing a complete copy of the Salmonella typhimurium glnA gene, or by pTIC5, a derivative of pKEK71-NotI containing a 1.8-kbp fragment that directs expression of CtxB with a 12-amino-acid epitope of the serine-rich Entamoeba histolytica protein fused to the amino terminus. Strain Peru2ΔglnA(pTIC5) produced 10-fold more SREHP-12-CtxB in supernatants than did ETR3, a Peru2-derivative strain containing the same fragment inserted on the chromosome. To assess immune responses to antigens expressed by this balanced lethal system in vivo, we inoculated germfree mice on days 0, 14, 28, and 42 with Peru2ΔglnA, Peru2ΔglnA(pKEK71-NotI), Peru2(pTIC5), Peru2ΔglnA(pTIC5), or ETR3. All V. cholerae strains were recoverable from stool for 8 to 12 days after primary inoculation, including Peru2ΔglnA; strains containing plasmids continued to harbor pKEK71-NotI or pTIC5 for 8 to 10 days after primary inoculation. Animals were sacrificed on day 56, and serum, stool and biliary samples were analyzed for immune responses. Vibriocidal antibody responses, reflective of in vivo colonization, were equivalent in all groups of animals. However, specific anti-CtxB immune responses in serum (P ≤ 0.05) and bile (P ≤ 0.001) were significantly higher in animals that received Peru2ΔglnA(pTIC5) than in those that received ETR3, confirming the advantage of higher-level antigen expression in vivo. The development of this balanced lethal system thus permits construction and maintenance of vaccine and vector strains of V. cholerae that express high levels of immunogenic antigens from plasmid vectors without the need for antibiotic selection pressure.


Sign in / Sign up

Export Citation Format

Share Document